Skip to main content
Premium Trial:

Request an Annual Quote

Variant Vaccine Push

GlaxoSmithKline and CureVac have teamed up in a €150 million ($180 million) collaboration to develop an mRNA-based COVID-19 vaccine against multiple viral variants, Reuters reports.

SARS-CoV-2 viral variants have been identified in the UK, South Africa, and Brazil, with some initial studies suggesting that existing vaccines may be less effective against the South African one. 

According to the companies, they will build on CureVac's current mRNA-based COVID-19 vaccine candidate, CVnCoV, to develop additional candidates — using both multivalent and monovalent approaches — with the goal of providing protection against a range of SARS-CoV-2 variants. Bloomberg adds that GSK and CureVac plan to have this candidate vaccine ready by 2022. It notes that GSK is also to manufacture 100 million doses of CureVac's current candidate vaccine, CVnCoV, which is Phase 2b/3 testing.

"We believe that next-generation vaccines will be crucial in the continued fight against COVID-19," Emma Walmsley, CEO of GSK, says in a statement.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.